{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29&page=3",
    "query": {
      "condition": "Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 864,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:36:17.063Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02204410",
      "title": "Omega-3 Supplementation to ADHD Medication in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder",
        "Deficient Emotional Self-Regulation"
      ],
      "interventions": [
        {
          "name": "Omega-3 Fatty Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "ADHD Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 21,
      "start_date": "2014-07",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-29",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204410"
    },
    {
      "nct_id": "NCT04421248",
      "title": "Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder Combined"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Donald Gilbert, MD, MS, FAAN, FAAP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "8 Years to 12 Years"
      },
      "enrollment_count": 214,
      "start_date": "2020-09-01",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421248"
    },
    {
      "nct_id": "NCT04016779",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 374,
      "start_date": "2019-11-20",
      "completion_date": "2020-10-10",
      "has_results": true,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 37,
      "location_summary": "Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04016779"
    },
    {
      "nct_id": "NCT00586573",
      "title": "Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "memantine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2007-03",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586573"
    },
    {
      "nct_id": "NCT01075672",
      "title": "Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obsessive Compulsive Disorder",
        "Body Dysmorphic Disorder",
        "Tourette Syndrome",
        "Trichotillomania",
        "Panic Disorder",
        "Social Phobia",
        "Generalized Anxiety Disorder",
        "Depression",
        "Post-Traumatic Stress Disorder",
        "Attention Deficit Hyperactivity Disorder",
        "Eating Disorder",
        "Specific Phobia",
        "General Medical Condition"
      ],
      "interventions": [
        {
          "name": "Cognitive behavioral therapy (CBT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2010-01",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01075672"
    },
    {
      "nct_id": "NCT00247572",
      "title": "Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity",
        "Amphetamine-Related Disorders",
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "NRP104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New River Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-09",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2007-11-05",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00247572"
    },
    {
      "nct_id": "NCT05357495",
      "title": "Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Disruptive Mood Dysregulation Disorder",
        "Attention Deficit Hyperactivity Disorder",
        "Normal Physiology"
      ],
      "interventions": [
        {
          "name": "Affective Posner fMRI frustration induction task",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-01-05",
      "completion_date": "2023-01-05",
      "has_results": false,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05357495"
    },
    {
      "nct_id": "NCT06388694",
      "title": "Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Attention-deficit Hyperactivity"
      ],
      "interventions": [
        {
          "name": "Pharmacist Care",
          "type": "OTHER"
        },
        {
          "name": "Primary Care Physician Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 315,
      "start_date": "2024-05-06",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-30",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388694"
    },
    {
      "nct_id": "NCT00419445",
      "title": "Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "GTS21/Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CoMentis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2007-02",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2010-09-10",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Durham, North Carolina",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419445"
    },
    {
      "nct_id": "NCT00191048",
      "title": "Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder",
        "Comorbid Dyslexia"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "10 Years to 16 Years"
      },
      "enrollment_count": 105,
      "start_date": "2003-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-11-18T20:36:17.063Z",
      "location_count": 8,
      "location_summary": "Rolling Hills Estate, California • Maitland, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Rolling Hills Estate",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Libertyville",
          "state": "Illinois"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00191048"
    }
  ]
}